Pancreatic cancer (PC) remains an incurable disease with few treatment options Recently, promising targets have been identified and novel therapeutic drugs are currently under development in KRAS wild-type PC. It has been reported that KRAS wild-type PC has the genomic alterations such as oncogenic derivers and kinase fusions. NRG1 fusion, which encodes the neuregulin 1 and is the main ligands for ERRB3, has been identified in approximately half of younger patients with PC with KRAS wild-type tumors by RNA sequencing. There are several promising targeted therapies for NRG1 fusion-positive tumors, such as EGFR-tyrosine kinase inhibitor, HER3, HER2 antibodies. BRAF, NTRK, and ALK fusion are also potentially actionable alterations in KRAS wild-type PC and novel therapies targeting certain aberrations have shown activity in clinical trials.

胰腺癌 (PC) 仍然是一种治疗选择很少的不治之症 最近，已经确定了有希望的靶点，目前正在开发KRAS野生型 PC 中的新型治疗药物。据报道，KRAS野生型 PC 具有基因组改变，如致癌衍生和激酶融合。NRG1融合编码神经调节蛋白 1 并且是 ERRB3 的主要配体，已通过 RNA 测序在大约一半患有KRAS野生型肿瘤的年轻 PC 患者中发现。针对NRG1融合阳性肿瘤有几种有前景的靶向疗法，例如 EGFR-酪氨酸激酶抑制剂、HER3、HER2 抗体。BRAF , NTRK和ALK融合也是KRAS野生型 PC 中潜在可行的改变，针对某些畸变的新疗法已在临床试验中显示出活性。